Show simple item record

dc.contributor.advisorLoren D. Walensky.
dc.contributor.authorMourtada, Rida.en_US
dc.contributor.otherHarvard--MIT Program in Health Sciences and Technology.en_US
dc.date.accessioned2021-10-15T15:29:20Z
dc.date.available2021-10-15T15:29:20Z
dc.date.copyright2018en_US
dc.date.issued2018en_US
dc.identifier.urihttps://hdl.handle.net/1721.1/132987
dc.descriptionThesis: Ph. D. in Medical Engineering and Medical Physics, Harvard-MIT Program in Health Sciences and Technology, June, 2018en_US
dc.descriptionCataloged from the official PDF version of thesis.en_US
dc.descriptionIncludes bibliographical references.en_US
dc.description.abstractAntibiotic resistance is a global health emergency that mandates new drug development strategies. Natural antimicrobial peptides (AMPs) have been long-recognized as a potential source of bacteriolytic drugs, but the shortcomings of non-specific membrane toxicity, proteolytic instability, and in vivo toxicity have stymied their clinical translation. Here, we subjected expansive stapled-peptide libraries of the magainin II (Mag2) AMP to structure-function analyses and uncovered the biophysical and mechanistic determinants that allow for the rational design of stapled AMPs (StAMPs) that are bacterial-membrane selective, proteolytically-stable, well tolerated in mice upon intravenous administration, and most importantly, overcome even the most antibiotic-resistant bacteria, including colistin-resistant A. baumannii and mobilized colistin resistance plasmid-bearing E. coli. Specifically, we discovered that the topographic continuity and strength of hydrophobic networks, in the context of alpha-helical amphipathic cationic peptides, dictates both the selectivity and mechanism of membrane lysis. We further harnessed our results to develop an algorithm for the design of a new generation of non-toxic, bacterial-selective StAMPs for clinical development.en_US
dc.description.statementofresponsibilityby Rida Mourtada.en_US
dc.format.extent189 pagesen_US
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsMIT theses may be protected by copyright. Please reuse MIT thesis content according to the MIT Libraries Permissions Policy, which is available through the URL provided.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582en_US
dc.subjectHarvard--MIT Program in Health Sciences and Technology.en_US
dc.titleEngineering membrane-selective antibiotic peptides to combat multidrug resistanceen_US
dc.typeThesisen_US
dc.description.degreePh. D. in Medical Engineering and Medical Physicsen_US
dc.contributor.departmentHarvard University--MIT Division of Health Sciences and Technologyen_US
dc.identifier.oclc1263579513en_US
dc.description.collectionPh.D.inMedicalEngineeringandMedicalPhysics Harvard-MIT Program in Health Sciences and Technologyen_US
dspace.imported2021-10-15T15:29:20Zen_US
mit.thesis.degreeDoctoralen_US
mit.thesis.departmentHSTen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record